Antipsychotics can be used in the short term to manage dementia-related psychosis, but serious adverse effects can outweigh benefits. Novel antipsychotics or other agents may offer superior efficacy and safety. Explore the evidence in this CME activity.
Antipsychotics may have immunomodulatory effects that could increase the risk of disseminated infections. This study sought to estimate the effect of antipsychotics on incident bloodstream infections in adults with chronic obstructive pulmonary disease.
The objective of this study was to investigate the prevalence of depression, anxiety, and insomnia among hospital staff working in a tertiary care private hospital in India during the early period of the COVID-19 pandemic.
Novel approaches are needed to assist rural primary care physicians in caring for older patients living with depression and pain who are at an elevated suicide risk. Read this article to find out more about the PREDICTOR model.
The link between suicidality and interpersonal difficulties extends the traditional approach of comprehending suicide as mainly related to depression. This study of adult outpatients investigated the link between separation anxiety disorder and suicidality.
Self-isolation measures, while important in curbing the spread and impact of COVID-19, are likely to increase rates of anxiety and depression. Here, a case is presented of COVID-19–related anxiety leading to late-onset psychotic and catatonic depression.
Optimal intervention for patients experiencing PTSD often includes prolonged follow-up that applies both talk and drug therapies in a supportive environment. This narrative review describes psychotherapeutic and pharmacologic approaches to treat PTSD.
Are women with vaginismus more susceptible to developing bipolar disorder? This study investigated the affective temperaments of women with vaginismus compared to healthy controls. The results may surprise you.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”